| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Respiratory Tract Infections | 32 | 2021 | 6817 | 1.58 | Why? |
| Immunity, Maternally-Acquired | 4 | 2018 | 179 | 1.49 | Why? |
| Respiratory Syncytial Virus Infections | 13 | 2020 | 1234 | 1.44 | Why? |
| Hematopoietic Stem Cell Transplantation | 15 | 2020 | 2426 | 1.22 | Why? |
| Rhinovirus | 12 | 2020 | 979 | 1.14 | Why? |
| Gastroenteritis | 4 | 2020 | 489 | 1.01 | Why? |
| Picornaviridae Infections | 6 | 2018 | 544 | 1.00 | Why? |
| Respiratory Syncytial Virus, Human | 9 | 2021 | 846 | 0.97 | Why? |
| Rotavirus Infections | 4 | 2020 | 355 | 0.95 | Why? |
| Rotavirus Vaccines | 3 | 2019 | 203 | 0.89 | Why? |
| Paramyxoviridae Infections | 6 | 2020 | 364 | 0.88 | Why? |
| Metapneumovirus | 9 | 2019 | 465 | 0.84 | Why? |
| Foscarnet | 1 | 2018 | 13 | 0.73 | Why? |
| Adenovirus Infections, Human | 2 | 2017 | 145 | 0.73 | Why? |
| Rotavirus | 2 | 2020 | 329 | 0.71 | Why? |
| Ganciclovir | 1 | 2018 | 97 | 0.68 | Why? |
| Organophosphonates | 1 | 2017 | 85 | 0.68 | Why? |
| Infant | 45 | 2021 | 30274 | 0.68 | Why? |
| Cytosine | 1 | 2017 | 92 | 0.67 | Why? |
| Severe Combined Immunodeficiency | 1 | 2018 | 107 | 0.65 | Why? |
| Immunocompromised Host | 11 | 2020 | 5150 | 0.64 | Why? |
| Nepal | 13 | 2020 | 1004 | 0.62 | Why? |
| Child Day Care Centers | 3 | 2018 | 208 | 0.61 | Why? |
| Influenza Vaccines | 11 | 2019 | 2941 | 0.59 | Why? |
| Virus Diseases | 10 | 2020 | 3779 | 0.57 | Why? |
| Influenza, Human | 16 | 2020 | 10779 | 0.51 | Why? |
| Immunization Schedule | 4 | 2019 | 1305 | 0.50 | Why? |
| Infant, Premature | 1 | 2017 | 883 | 0.48 | Why? |
| Orthomyxoviridae | 5 | 2019 | 1168 | 0.47 | Why? |
| Washington | 11 | 2021 | 1722 | 0.47 | Why? |
| Cytomegalovirus Infections | 1 | 2018 | 667 | 0.44 | Why? |
| Viruses | 3 | 2021 | 2238 | 0.43 | Why? |
| Whooping Cough | 3 | 2017 | 201 | 0.42 | Why? |
| Viremia | 1 | 2018 | 1020 | 0.41 | Why? |
| Child, Preschool | 35 | 2021 | 36283 | 0.41 | Why? |
| Infant, Newborn | 22 | 2020 | 23105 | 0.39 | Why? |
| Sequence Analysis, RNA | 1 | 2018 | 2290 | 0.38 | Why? |
| Respiratory Syncytial Virus Vaccines | 3 | 2019 | 104 | 0.37 | Why? |
| Vaccination | 12 | 2019 | 19050 | 0.35 | Why? |
| Enterovirus D, Human | 2 | 2019 | 96 | 0.35 | Why? |
| Respirovirus Infections | 3 | 2017 | 90 | 0.34 | Why? |
| Diphtheria-Tetanus-Pertussis Vaccine | 2 | 2019 | 92 | 0.34 | Why? |
| Parainfluenza Virus 3, Human | 2 | 2017 | 67 | 0.34 | Why? |
| Fetal Blood | 3 | 2018 | 573 | 0.30 | Why? |
| Rural Population | 7 | 2020 | 2408 | 0.29 | Why? |
| Immunity | 1 | 2017 | 2651 | 0.29 | Why? |
| Viral Load | 7 | 2021 | 15850 | 0.28 | Why? |
| Coronavirus | 12 | 2020 | 18339 | 0.27 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2007 | 260 | 0.27 | Why? |
| Nasal Lavage Fluid | 2 | 2015 | 43 | 0.26 | Why? |
| Child | 33 | 2021 | 70012 | 0.26 | Why? |
| Enterovirus Infections | 2 | 2019 | 404 | 0.26 | Why? |
| Coinfection | 4 | 2019 | 6820 | 0.25 | Why? |
| Female | 61 | 2021 | 380317 | 0.24 | Why? |
| Prospective Studies | 15 | 2021 | 43301 | 0.23 | Why? |
| Respirovirus | 3 | 2019 | 122 | 0.23 | Why? |
| Cystic Fibrosis | 1 | 2011 | 1104 | 0.22 | Why? |
| Child, Hospitalized | 2 | 2018 | 556 | 0.22 | Why? |
| Measles | 2 | 2019 | 608 | 0.22 | Why? |
| Population Surveillance | 6 | 2021 | 4967 | 0.22 | Why? |
| Cross Infection | 4 | 2017 | 8675 | 0.22 | Why? |
| Immunization, Passive | 1 | 2017 | 10067 | 0.22 | Why? |
| Mothers | 4 | 2019 | 1624 | 0.21 | Why? |
| Metagenomics | 2 | 2017 | 823 | 0.21 | Why? |
| Adolescent | 30 | 2021 | 86841 | 0.20 | Why? |
| Sequence Homology | 2 | 2018 | 448 | 0.20 | Why? |
| Pertussis Vaccine | 2 | 2017 | 89 | 0.20 | Why? |
| Humans | 89 | 2021 | 930598 | 0.20 | Why? |
| Male | 53 | 2021 | 367725 | 0.20 | Why? |
| Somatic Hypermutation, Immunoglobulin | 1 | 2020 | 283 | 0.20 | Why? |
| Pregnancy | 12 | 2021 | 23879 | 0.19 | Why? |
| Homeless Persons | 2 | 2020 | 1171 | 0.19 | Why? |
| Birth Weight | 2 | 2017 | 250 | 0.19 | Why? |
| Measles-Mumps-Rubella Vaccine | 2 | 2019 | 282 | 0.19 | Why? |
| Virus Shedding | 4 | 2020 | 5834 | 0.18 | Why? |
| Spectrometry, Mass, Electrospray Ionization | 1 | 2018 | 159 | 0.18 | Why? |
| Influenza A Virus, H3N2 Subtype | 2 | 2017 | 572 | 0.18 | Why? |
| United States | 20 | 2021 | 46150 | 0.18 | Why? |
| Enterovirus | 2 | 2019 | 402 | 0.17 | Why? |
| Specimen Handling | 3 | 2021 | 6190 | 0.17 | Why? |
| Respiratory Syncytial Viruses | 4 | 2019 | 612 | 0.17 | Why? |
| International Classification of Diseases | 1 | 2020 | 265 | 0.17 | Why? |
| Acute Kidney Injury | 1 | 2017 | 5762 | 0.17 | Why? |
| Antibodies, Bacterial | 2 | 2017 | 510 | 0.17 | Why? |
| RNA, Viral | 8 | 2021 | 32276 | 0.17 | Why? |
| Transplantation, Homologous | 2 | 2018 | 757 | 0.17 | Why? |
| Haemophilus Vaccines | 1 | 2017 | 76 | 0.16 | Why? |
| Rubella | 1 | 2018 | 127 | 0.16 | Why? |
| Hepatitis B Vaccines | 1 | 2019 | 245 | 0.16 | Why? |
| Tetanus | 1 | 2017 | 61 | 0.16 | Why? |
| High-Throughput Nucleotide Sequencing | 3 | 2017 | 3633 | 0.16 | Why? |
| Diphtheria | 1 | 2017 | 74 | 0.16 | Why? |
| Infant, Low Birth Weight | 4 | 2018 | 243 | 0.16 | Why? |
| Antiviral Agents | 5 | 2020 | 41703 | 0.16 | Why? |
| Infectious Disease Medicine | 1 | 2019 | 311 | 0.15 | Why? |
| Fucosyltransferases | 1 | 2015 | 3 | 0.15 | Why? |
| Transplantation Conditioning | 1 | 2018 | 323 | 0.15 | Why? |
| Family Health | 2 | 2020 | 731 | 0.15 | Why? |
| Pregnancy Trimester, Third | 1 | 2017 | 445 | 0.15 | Why? |
| Genotyping Techniques | 1 | 2018 | 360 | 0.15 | Why? |
| Weather | 1 | 2021 | 581 | 0.14 | Why? |
| Disease Eradication | 2 | 2018 | 581 | 0.14 | Why? |
| Bronchoalveolar Lavage Fluid | 2 | 2017 | 2309 | 0.14 | Why? |
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2018 | 511 | 0.14 | Why? |
| Antibodies, Viral | 9 | 2021 | 51949 | 0.13 | Why? |
| Cost of Illness | 3 | 2020 | 1903 | 0.13 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2021 | 13720 | 0.13 | Why? |
| Pediatrics | 2 | 2020 | 2969 | 0.13 | Why? |
| Transplant Recipients | 3 | 2019 | 4982 | 0.13 | Why? |
| Organ Transplantation | 2 | 2019 | 2616 | 0.13 | Why? |
| Pregnancy Complications, Infectious | 5 | 2021 | 11559 | 0.13 | Why? |
| Visitors to Patients | 1 | 2020 | 671 | 0.13 | Why? |
| Young Adult | 22 | 2021 | 93724 | 0.13 | Why? |
| Cytomegalovirus | 2 | 2018 | 600 | 0.13 | Why? |
| Incidence | 11 | 2021 | 25622 | 0.13 | Why? |
| Pneumococcal Infections | 1 | 2019 | 562 | 0.12 | Why? |
| Coronavirus Infections | 16 | 2020 | 253789 | 0.12 | Why? |
| Polymerase Chain Reaction | 6 | 2020 | 6740 | 0.12 | Why? |
| Sentinel Surveillance | 1 | 2020 | 1093 | 0.12 | Why? |
| Time Factors | 10 | 2018 | 31397 | 0.12 | Why? |
| Coronavirus 229E, Human | 1 | 2021 | 1241 | 0.12 | Why? |
| Hospitals, Pediatric | 2 | 2020 | 1792 | 0.12 | Why? |
| Human bocavirus | 1 | 2013 | 142 | 0.12 | Why? |
| Immunoglobulin G | 4 | 2020 | 21571 | 0.12 | Why? |
| Influenza B virus | 4 | 2017 | 815 | 0.12 | Why? |
| Genotype | 3 | 2020 | 4697 | 0.12 | Why? |
| Caliciviridae Infections | 1 | 2015 | 229 | 0.11 | Why? |
| Intensive Care Units, Neonatal | 1 | 2017 | 749 | 0.11 | Why? |
| Phylogeny | 6 | 2021 | 13341 | 0.11 | Why? |
| Premature Birth | 3 | 2019 | 2151 | 0.11 | Why? |
| Hepatitis B virus | 1 | 2019 | 882 | 0.11 | Why? |
| Population Density | 1 | 2017 | 694 | 0.11 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 1261 | 0.11 | Why? |
| Norovirus | 1 | 2015 | 294 | 0.11 | Why? |
| Nasal Cavity | 2 | 2020 | 909 | 0.11 | Why? |
| Nose | 1 | 2017 | 1093 | 0.11 | Why? |
| Parvoviridae Infections | 1 | 2013 | 222 | 0.11 | Why? |
| Molecular Epidemiology | 1 | 2016 | 1638 | 0.11 | Why? |
| Immunization | 2 | 2017 | 2019 | 0.11 | Why? |
| Hepatitis B | 1 | 2019 | 888 | 0.11 | Why? |
| Adenoviridae | 4 | 2010 | 1151 | 0.10 | Why? |
| Immune Evasion | 1 | 2021 | 2081 | 0.10 | Why? |
| Longitudinal Studies | 3 | 2021 | 9893 | 0.10 | Why? |
| Prevalence | 4 | 2020 | 25773 | 0.10 | Why? |
| Confidence Intervals | 1 | 2013 | 744 | 0.10 | Why? |
| Genome, Viral | 3 | 2021 | 13157 | 0.10 | Why? |
| Epidemiological Monitoring | 2 | 2020 | 3493 | 0.10 | Why? |
| Pregnancy Complications | 1 | 2021 | 1388 | 0.10 | Why? |
| Public Health Surveillance | 2 | 2020 | 3129 | 0.10 | Why? |
| Milk, Human | 1 | 2019 | 956 | 0.10 | Why? |
| Antibodies, Neutralizing | 3 | 2021 | 25288 | 0.10 | Why? |
| Vaccination Coverage | 1 | 2019 | 1249 | 0.10 | Why? |
| Cohort Studies | 7 | 2020 | 36005 | 0.09 | Why? |
| Odds Ratio | 3 | 2019 | 5861 | 0.09 | Why? |
| Ribavirin | 1 | 2016 | 1182 | 0.09 | Why? |
| Cross-Sectional Studies | 7 | 2021 | 53120 | 0.09 | Why? |
| Virology | 1 | 2013 | 489 | 0.09 | Why? |
| Bronchiolitis, Viral | 1 | 2008 | 71 | 0.09 | Why? |
| Parents | 2 | 2020 | 2758 | 0.09 | Why? |
| Adult | 29 | 2021 | 244371 | 0.09 | Why? |
| Risk Factors | 12 | 2020 | 71621 | 0.09 | Why? |
| Retrospective Studies | 13 | 2021 | 105322 | 0.09 | Why? |
| Bordetella pertussis | 2 | 2017 | 117 | 0.09 | Why? |
| Acute Disease | 1 | 2020 | 6029 | 0.08 | Why? |
| Pneumonia | 1 | 2007 | 5652 | 0.08 | Why? |
| Antibodies, Monoclonal | 3 | 2021 | 8041 | 0.08 | Why? |
| Nutritional Status | 1 | 2017 | 1403 | 0.08 | Why? |
| Seasons | 5 | 2019 | 4071 | 0.08 | Why? |
| Amino Acid Sequence | 1 | 2018 | 6049 | 0.08 | Why? |
| Immunization Programs | 1 | 2019 | 2006 | 0.08 | Why? |
| Disease Outbreaks | 4 | 2021 | 27595 | 0.08 | Why? |
| Hemagglutination Inhibition Tests | 1 | 2006 | 191 | 0.08 | Why? |
| Inpatients | 2 | 2019 | 5161 | 0.08 | Why? |
| Hospitalization | 7 | 2019 | 54280 | 0.08 | Why? |
| Severity of Illness Index | 4 | 2019 | 48226 | 0.08 | Why? |
| Nasopharynx | 3 | 2021 | 10224 | 0.08 | Why? |
| Coronaviridae Infections | 1 | 2009 | 442 | 0.07 | Why? |
| RNA Viruses | 1 | 2013 | 824 | 0.07 | Why? |
| Academic Medical Centers | 1 | 2017 | 3088 | 0.07 | Why? |
| Nasal Mucosa | 1 | 2013 | 1218 | 0.07 | Why? |
| Survival Analysis | 1 | 2018 | 7592 | 0.07 | Why? |
| Oxygen Inhalation Therapy | 1 | 2017 | 3629 | 0.07 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.07 | Why? |
| Hematologic Neoplasms | 1 | 2017 | 2105 | 0.07 | Why? |
| Evolution, Molecular | 1 | 2017 | 3691 | 0.06 | Why? |
| Sputum | 1 | 2011 | 1720 | 0.06 | Why? |
| Genetic Variation | 1 | 2017 | 3919 | 0.06 | Why? |
| Patient Outcome Assessment | 2 | 2017 | 707 | 0.06 | Why? |
| Patient Discharge | 1 | 2017 | 5696 | 0.06 | Why? |
| Pneumonia, Viral | 11 | 2020 | 243684 | 0.05 | Why? |
| Developing Countries | 1 | 2017 | 4283 | 0.05 | Why? |
| Epidemics | 1 | 2021 | 6407 | 0.05 | Why? |
| Betacoronavirus | 7 | 2020 | 204454 | 0.05 | Why? |
| Spike Glycoprotein, Coronavirus | 2 | 2021 | 37182 | 0.05 | Why? |
| Genetic Predisposition to Disease | 1 | 2015 | 4027 | 0.05 | Why? |
| T-Lymphocytes | 1 | 2017 | 6670 | 0.05 | Why? |
| Patient Acceptance of Health Care | 1 | 2018 | 5002 | 0.05 | Why? |
| Radiography | 1 | 2007 | 1576 | 0.05 | Why? |
| Vaccines, Inactivated | 1 | 2006 | 1562 | 0.05 | Why? |
| Vaccines, Attenuated | 2 | 2019 | 952 | 0.05 | Why? |
| Comorbidity | 2 | 2021 | 34796 | 0.05 | Why? |
| Seroepidemiologic Studies | 3 | 2020 | 10017 | 0.05 | Why? |
| Lactation | 1 | 2021 | 361 | 0.05 | Why? |
| Virulence Factors, Bordetella | 1 | 2017 | 14 | 0.05 | Why? |
| Pertussis Toxin | 1 | 2017 | 19 | 0.04 | Why? |
| Viral Proteins | 1 | 2017 | 7370 | 0.04 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2020 | 8843 | 0.04 | Why? |
| Middle Aged | 16 | 2021 | 270681 | 0.04 | Why? |
| Bacterial Outer Membrane Proteins | 1 | 2017 | 60 | 0.04 | Why? |
| Binding Sites | 2 | 2021 | 6201 | 0.04 | Why? |
| Likelihood Functions | 1 | 2020 | 719 | 0.04 | Why? |
| Influenza A virus | 3 | 2017 | 2234 | 0.04 | Why? |
| Infant, Small for Gestational Age | 1 | 2017 | 151 | 0.04 | Why? |
| Bone Marrow Transplantation | 2 | 1997 | 343 | 0.04 | Why? |
| Medically Uninsured | 1 | 2019 | 237 | 0.04 | Why? |
| Growth Disorders | 1 | 2017 | 91 | 0.04 | Why? |
| Anthropometry | 1 | 2017 | 233 | 0.04 | Why? |
| Risk Assessment | 2 | 2017 | 25439 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.04 | Why? |
| Community-Acquired Infections | 2 | 2007 | 2328 | 0.04 | Why? |
| Randomized Controlled Trials as Topic | 3 | 2020 | 10649 | 0.04 | Why? |
| Anti-Bacterial Agents | 1 | 2018 | 10083 | 0.04 | Why? |
| Certification | 1 | 2019 | 261 | 0.04 | Why? |
| Multiplex Polymerase Chain Reaction | 2 | 2015 | 1439 | 0.04 | Why? |
| Respiratory System | 1 | 2008 | 3213 | 0.04 | Why? |
| Fever | 1 | 2013 | 7795 | 0.04 | Why? |
| Immunocompetence | 1 | 1997 | 280 | 0.04 | Why? |
| Nucleoproteins | 1 | 2017 | 223 | 0.04 | Why? |
| Viral Fusion Proteins | 1 | 2019 | 399 | 0.04 | Why? |
| Emergency Service, Hospital | 1 | 2019 | 14232 | 0.03 | Why? |
| Age Factors | 3 | 2021 | 21039 | 0.03 | Why? |
| Streptococcus pneumoniae | 1 | 2019 | 827 | 0.03 | Why? |
| Neoplasms | 3 | 2019 | 17251 | 0.03 | Why? |
| Protein Binding | 2 | 2021 | 11430 | 0.03 | Why? |
| Common Cold | 1 | 2020 | 645 | 0.03 | Why? |
| Feces | 2 | 2020 | 4235 | 0.03 | Why? |
| Antigens, Viral | 2 | 2013 | 6298 | 0.03 | Why? |
| Bronchoalveolar Lavage | 1 | 2017 | 603 | 0.03 | Why? |
| Career Choice | 1 | 2019 | 498 | 0.03 | Why? |
| Aged | 10 | 2021 | 215776 | 0.03 | Why? |
| Logistic Models | 2 | 2019 | 9089 | 0.03 | Why? |
| Antibody Formation | 1 | 2006 | 4038 | 0.03 | Why? |
| Gestational Age | 1 | 2018 | 1488 | 0.03 | Why? |
| Viral Vaccines | 2 | 2020 | 7560 | 0.03 | Why? |
| Observational Studies as Topic | 1 | 2020 | 1887 | 0.03 | Why? |
| Allografts | 1 | 2016 | 761 | 0.03 | Why? |
| Epitopes, B-Lymphocyte | 1 | 2020 | 1267 | 0.03 | Why? |
| Sex Factors | 2 | 2020 | 11014 | 0.03 | Why? |
| Treatment Outcome | 5 | 2020 | 51732 | 0.03 | Why? |
| Respiratory Therapy | 1 | 2018 | 918 | 0.03 | Why? |
| Steroids | 1 | 2017 | 904 | 0.03 | Why? |
| Regression Analysis | 1 | 2018 | 2484 | 0.03 | Why? |
| Spatio-Temporal Analysis | 1 | 2017 | 1182 | 0.03 | Why? |
| Molecular Diagnostic Techniques | 2 | 2020 | 4239 | 0.03 | Why? |
| Bayes Theorem | 1 | 2020 | 3237 | 0.03 | Why? |
| Alaska | 1 | 2010 | 100 | 0.03 | Why? |
| Interviews as Topic | 1 | 2020 | 1952 | 0.03 | Why? |
| Paramyxoviridae | 1 | 2010 | 67 | 0.03 | Why? |
| Respiratory Function Tests | 1 | 2017 | 1755 | 0.03 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.03 | Why? |
| Mortality | 2 | 2017 | 7132 | 0.03 | Why? |
| Adrenal Cortex Hormones | 2 | 2018 | 6537 | 0.03 | Why? |
| Gene Frequency | 1 | 2015 | 1210 | 0.03 | Why? |
| Recurrence | 1 | 2020 | 3675 | 0.02 | Why? |
| Reagent Kits, Diagnostic | 1 | 2020 | 2149 | 0.02 | Why? |
| Cross Reactions | 1 | 2021 | 4374 | 0.02 | Why? |
| Hospitals | 2 | 2020 | 11793 | 0.02 | Why? |
| Family Characteristics | 1 | 2020 | 2551 | 0.02 | Why? |
| Clinical Laboratory Techniques | 3 | 2020 | 23402 | 0.02 | Why? |
| Cities | 1 | 2021 | 4937 | 0.02 | Why? |
| Epitopes | 1 | 2021 | 4113 | 0.02 | Why? |
| Pandemics | 9 | 2021 | 389249 | 0.02 | Why? |
| Case-Control Studies | 2 | 2019 | 17671 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2017 | 2830 | 0.02 | Why? |
| Cluster Analysis | 1 | 2016 | 3001 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2019 | 5440 | 0.02 | Why? |
| Protein Domains | 1 | 2021 | 6563 | 0.02 | Why? |
| HEK293 Cells | 1 | 2021 | 8394 | 0.02 | Why? |
| Neutralization Tests | 1 | 2021 | 6698 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2017 | 2259 | 0.02 | Why? |
| Symptom Assessment | 1 | 2021 | 4967 | 0.02 | Why? |
| Fluorescent Antibody Technique, Indirect | 1 | 2008 | 393 | 0.02 | Why? |
| Immunoglobulin A | 1 | 2019 | 3567 | 0.02 | Why? |
| Point-of-Care Systems | 1 | 2020 | 2955 | 0.02 | Why? |
| Nanoparticles | 1 | 2018 | 2040 | 0.02 | Why? |
| Serologic Tests | 1 | 2020 | 4359 | 0.02 | Why? |
| Aged, 80 and over | 3 | 2021 | 88759 | 0.02 | Why? |
| Cell Line | 1 | 2021 | 12040 | 0.02 | Why? |
| Diagnostic Tests, Routine | 1 | 2017 | 2643 | 0.02 | Why? |
| Canada | 1 | 2018 | 6018 | 0.02 | Why? |
| B-Lymphocytes | 1 | 2020 | 4418 | 0.02 | Why? |
| World Health Organization | 1 | 2018 | 4213 | 0.02 | Why? |
| Pregnant Women | 1 | 2018 | 2535 | 0.02 | Why? |
| Absenteeism | 1 | 2006 | 287 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2016 | 4758 | 0.02 | Why? |
| Pregnancy Outcome | 1 | 2017 | 3803 | 0.02 | Why? |
| Early Diagnosis | 1 | 2013 | 2443 | 0.02 | Why? |
| Receptors, Virus | 1 | 2020 | 5659 | 0.02 | Why? |
| Societies, Medical | 1 | 2019 | 6907 | 0.02 | Why? |
| School Health Services | 1 | 2006 | 294 | 0.02 | Why? |
| Follow-Up Studies | 1 | 2021 | 17020 | 0.01 | Why? |
| Models, Theoretical | 1 | 2021 | 6659 | 0.01 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 7868 | 0.01 | Why? |
| Mice | 1 | 2021 | 21357 | 0.01 | Why? |
| Travel | 1 | 2020 | 7220 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2019 | 8495 | 0.01 | Why? |
| Immunoassay | 1 | 2017 | 4485 | 0.01 | Why? |
| Ambulatory Care | 1 | 2018 | 4947 | 0.01 | Why? |
| Toxoids | 1 | 1999 | 9 | 0.01 | Why? |
| Contact Tracing | 1 | 2020 | 8448 | 0.01 | Why? |
| Health Services | 1 | 2006 | 765 | 0.01 | Why? |
| Spain | 1 | 2018 | 15545 | 0.01 | Why? |
| DNA, Viral | 1 | 2010 | 2521 | 0.01 | Why? |
| Macaca mulatta | 1 | 2009 | 3716 | 0.01 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.01 | Why? |
| Cells, Cultured | 1 | 2009 | 5835 | 0.01 | Why? |
| Infection Control | 1 | 2007 | 23131 | 0.01 | Why? |
| Dose-Response Relationship, Immunologic | 1 | 1999 | 593 | 0.01 | Why? |
| Proportional Hazards Models | 1 | 2010 | 6543 | 0.01 | Why? |
| Disease Progression | 1 | 2016 | 13580 | 0.01 | Why? |
| Animals | 2 | 2021 | 78931 | 0.01 | Why? |
| Mutation | 1 | 2017 | 12376 | 0.01 | Why? |
| Picornaviridae | 1 | 1997 | 123 | 0.01 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 8811 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 11367 | 0.01 | Why? |
| Global Health | 1 | 2018 | 13911 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2017 | 22116 | 0.01 | Why? |
| Immunization, Secondary | 1 | 1999 | 1649 | 0.01 | Why? |
| Dose-Response Relationship, Drug | 1 | 1999 | 3776 | 0.01 | Why? |
| Double-Blind Method | 1 | 1999 | 5988 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2006 | 43792 | 0.00 | Why? |